Supporting Studies Sample Clauses

Supporting Studies. Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 4 pages were omitted. [**] Milestone 2
Sample 1
AutoNDA by SimpleDocs
Supporting Studies. The proposals included in the General Urban Plan will be substantiated by analytical, advisory and prospective supporting studies:11 The analytical supporting studies concern the evolution of the locality and of its characteristics; The advisory supporting studies emphasize the requirements and options available to the population and other stakeholders in relation to urban development. This type of studies may be prepared based on surveys and social-urban surveys among the population, experts, institutions and other stakeholders; The prospective supporting studies deliver forecasts, scenarios or alternatives for various sectoral fields. Thus, the supporting studies underpin the urban regulations which are part of the General Urban Plan. For this reason, they have to include up-to-date and relevant conclusions for the urban regulations included in the General Urban Plan. Therefore, the analyses in the supporting studies have to rely on updated data that are less than three years older than the date of the supporting studies. Where this is not possible, the tenderer has to use the most recent data available and to defend its choice. Moreover, previous studies, research and projects may be used, provided the information contained therein remain valid and relevant for the purposes of the General Urban Plan.
Sample 1

Related to Supporting Studies

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Regulatory Filings NYISO and Connecting Transmission Owner shall file this Agreement (and any amendment hereto) with the appropriate Governmental Authority, if required. Any information related to studies for interconnection asserted by Developer to contain Confidential Information shall be treated in accordance with Article 22 of this Agreement and Attachment F to the ISO OATT. If the Developer has executed this Agreement, or any amendment thereto, the Developer shall reasonably cooperate with NYISO and Connecting Transmission Owner with respect to such filing and to provide any information reasonably requested by NYISO and Connecting Transmission Owner needed to comply with Applicable Laws and Regulations.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!